Preventive Cardiology - The Horizon Study. The Horizon Study is a randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with known cardiovascular disease. This study is being conducted by Dr. Paul Thompson and Preventive Cardiology..